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Potassium Channel Activators Protect the
N-Methyl-D-Aspartate–Induced Cerebral Vascular Dilation
After Combined Hypoxia and Ischemia in Piglets
Roland Veltkamp, MD; Ferenc Domoki, MD; Ferenc Bari, PhD; David W. Busija, PhD
Background and Purpose—Cerebral arteriolar dilation to N-methyl-D-aspartate (NMDA) is a neuronally mediated
multistep process that is sensitive to cerebral hypoxia and ischemia (H/I). We tested the hypothesis that topical
pretreatment with the selective potassium channel agonists NS1619 and aprikalim preserves the vascular response to
NMDA after consecutive H/I.
Methods—Pial arteriolar diameters were measured in anesthetized piglets with the use of a closed cranial window and
intravital microscopy. Arteriolar responses to NMDA (1025, 531025, and 1024 mol/L) were recorded before and 1 hour
after 10 minutes of hypoxia (8.5% O2 in N2) plus 10 minutes of ischemia (H/I). Ischemia was induced by increasing
intracranial pressure. Subgroups were topically pretreated with 1025 mol/L NS1619, 1026 mol/L aprikalim, 1026 mol/L
calcitonin gene–related peptide (CGRP), or 1025 mol/L papaverine. We also examined the effects of H/I on vascular
responses to kainate (1024 mol/L) to assess specificity of neuronal injury.
Results—Arteriolar responses to NMDA were significantly attenuated after H/I. Baseline compared with post-H/I arteriolar
diameters were 964% versus 362% at 1025 mol/L, 2264% versus 462% at 531025 mol/L, and 3364% versus 762%
at 1024 mol/L (mean6SE; all P,.05, n57). Pretreatment with NS1619 and aprikalim preserved the arteriolar responses
to NMDA after H/I. For NS1619 (n56), values were as follows: 962% versus 664% at 1025 mol/L, 1966% versus
2165% at 531025 mol/L, and 3563% versus 3165% at 1024 mol/L. For aprikalim (n57), values were as follows:
662% versus 862% at 1025 mol/L, 2266% versus 1563% at 531025 mol/L, and 4165% versus 3266% at 1024
mol/L. In contrast, piglets pretreated with CGRP (n56) or papaverine (n55) showed no preservation of the vascular
response to NMDA after H/I, although these compounds dilated the arterioles to an extent similar to that with
NS1619/aprikalim. Kainate-induced arteriolar dilation (n56) was largely preserved after H/I compared with preische-
mic responses.
Conclusions—(1) Vascular responses of cerebral arterioles to NMDA after H/I are preserved by pretreatment with
NS1619 or aprikalim, indicating a neuroprotective effect. (2) CGRP and papaverine do not preserve the vascular
response to NMDA despite causing vasodilation similar to that with NS1619 or aprikalim. This suggests that
activation of potassium channels on neurons accounts for the protective effect of potassium channel agonists. (3)
Preserved arteriolar dilation to kainate suggests largely intact functioning of neuronal nitric oxide synthase after
H/I. (Stroke. 1998;29:837-843.)
Key Words: cerebral arterioles n neuronal protection n N-methyl-D-aspartate n potassium channels
Glutamate is an important excitatory amino acid neuro-transmitter in the central nervous system. It can bind to
three different ionotropic glutamate receptor subtypes on
neurons named after specific synthetic analogues: NMDA,
kainate, and AMPA. Activation of neuronal NMDA and
kainate receptors causes cerebral arteriolar dilation in differ-
ent animal species, which is mediated in part or even totally
by NO-dependent mechanisms.1–6 This sequence may repre-
sent one of the mechanisms coupling local cerebral metabo-
lism to blood flow.
See Editorial Comment, page 842
We and others have shown that global H/I severely attenuates
or abolishes the arteriolar response to NMDA7–9 as well as to
other vasodilating agents such as CGRP and aprikalim.10,11
Impaired neuronal-vascular coupling in combination with patho-
logical metabolic and electrophysiological processes may con-
tribute to delayed cerebral damage in brain H/I.12
From an experimental point of view, the integrity of the
neuronal-vascular axis can be used as a model for the study of
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potential neuroprotective agents. The rationale of this model
is based on the observation that the arteriolar response to a
neuron-mediated vasodilator (eg, NMDA) is attenuated after
ischemia compared with preischemic baseline measurements.
An experimental intervention is considered neuroprotective if
it preserves the original vascular responsiveness to NMDA
after ischemia.
Recent advances in the molecular biology and pharmacol-
ogy of potassium channels13 have enabled the investigation of
potential therapeutic effects of K1 channel agonists. Different
types of ligand-operated channels have been characterized
according to their primary regulatory or gating mechanism.
Opening of K1 channels leads to efflux of K1 ions, which is
a mechanism for recovering (repolarization) and/or enhanc-
ing (hyperpolarization) the membrane potential of a cell.14
Potassium channel activation may therefore counteract ische-
mia-induced depolarizations. In previous studies K1 channel
agonists blocked ischemia-induced glutamate release in rat
hippocampal slices15 and prevented the ischemia-induced
expression of immediate early genes in a rat model of global
ischemia.16
The purpose of the present study was to test the hypothesis
that potassium channel agonists preserve the NMDA-induced
cerebral arteriolar dilation after consecutive H/I. Specifically,
we examined the effects of NS1619 and aprikalim, putatively
specific openers of calcium-dependent potassium channels
(KCa) and ATP-dependent potassium channels (KATP), respec-
tively. We also examined the effects of CGRP and papaverine
to determine whether protective effects were independent of
arteriolar dilation. Furthermore, we investigated whether the
combined H/I protocol attenuated the kainate-induced arte-
riolar dilation, which had been resistant to ischemia alone in
an earlier study.6 Kainate-induced arteriolar dilation shares
features of NMDA-induced arteriolar responses in that at
least one half of the vascular response is NO dependent.
Materials and Methods
Surgical Preparation
Experiments were performed on newborn pigs (1 to 7 days) of either
sex weighing 1 to 2 kg. The procedures used in the study were
approved by the Institutional Animal Care and Use Committee. The
piglets were initially anesthetized with sodium thiopental (30 mg/kg
IP) and later with a-chloralose (75 mg/kg IV). Additional amounts of
a-chloralose were given as needed to maintain a stable level of
anesthesia. The piglets were intubated by a tracheotomy and artifi-
cially ventilated. A femoral artery and vein were cannulated with
polyethylene tubing (PE-90). Arterial blood gases and pH were
repetitively measured, and rectal temperature was continually mon-
itored. These parameters were kept within the normal physiological
range. The head of each piglet was fixed in a stereotaxic apparatus.
Approximately 3 mL of CSF was withdrawn from the cisterna
magna. The scalp was cut, and the connective tissue over the parietal
bone was removed. A circular craniectomy (19 mm in diameter) was
made in the left parietal bone. The dura was cut and reflected over
the skull. A stainless steel and glass cranial window with three ports
was put into the opening, sealed with bone wax, and cemented with
cyanoacrylate ester (SuperGlue) followed by one or two layers of
dental acrylic. The closed window was filled with aCSF that was
warmed to 37°C and equilibrated with 6% O2, 6.5% CO2, balance N2.
Arterioles were observed with a microscope (Wild M36) equipped
with a television camera (Panasonic), and arteriolar diameter was
measured with a video microscaler (IV-550, For-A Co).
Cerebral H/I
Cerebral hypoxia was induced by artificial ventilation with 8.5% O2,
balance N2 over 10 minutes. Arterial blood gases were measured 8
minutes after hypoxia was started. Ten minutes of hypoxia were
immediately followed by 10 minutes of global cerebral ischemia.
Cerebral ischemia was produced by implantation of a hollow brass
bolt in the left parietal cranium 20 mm rostral to the cranial window.
A 3-mm hole was drilled in the skull with an electric drill with a
toothless bit, and the dura was exposed. The hollow bolt was inserted
and secured in place with cyanoacrylate ester and dental acrylic.
After implantation of the window and the bolt, aCSF was allowed to
equilibrate with the periarachnoid CSF for 20 minutes. To induce
ischemia, aCSF was infused to maintain intracranial pressure above
mean arterial pressure so that blood flow through pial vessels was
stopped. Venous blood was withdrawn as necessary to maintain
mean arterial pressure near normal values. At the end of the
10-minute period of ischemia, the infusion tube was clamped, and
the intracranial pressure was allowed to return to preischemia values.
The heparinized blood was reinfused intravenously.
Experimental Design
At the beginning of each experiment the cranial window was flushed
several times with aCSF until a stable baseline was observed. Then
arteriolar responses to NMDA (1025, 531025, 1024 mol/L) were
determined. Each dose of NMDA was introduced into the window,
the infusion was stopped, and arteriolar diameter was recorded over
the next 5 to 10 minutes. Afterward the window was flushed with
aCSF. The arteriolar diameter returned to baseline within 15 to 20
minutes.
Animals were divided into five experimental groups. In group 1
(n57) arteriolar responses to NMDA were recorded before (see
above) and 1 hour after 10 minutes of hypoxia plus 10 minutes of
global ischemia. In addition to this protocol, the other four groups
were pretreated with a topical infusion 10 minutes before H/I of
either NS1619 1025 mol/L (group 2, n56); aprikalim 1026 mol/L
(group 3, n57); CGRP 1026 mol/L (group 4, n56); or papaverine,
1025 mol/L (group 5, n55). Arteriolar responses to these drugs were
recorded during the infusion period. The drugs were washed away
just before the beginning of hypoxia. In groups 1 and 4, 1024 mol/L
sodium nitroprusside was applied topically after the NMDA re-
sponses 1 hour after H/I were measured to examine the vascular
responsiveness to exogenous NO.
In another experiment, the cerebral arteriolar responses to 1024
mol/L kainate (group 5, n56) before and 1 hour after H/I were
determined.
Drugs
We used NMDA (Sigma), kainate (Sigma), sodium nitroprusside
(Sigma), NS1619 (Research Biochemicals International), aprikalim
(Rhone-Roulenc Rorer), CGRP (Research Biochemicals Internation-
al), and papaverine (Sigma).
Statistical Analysis
Data are expressed as mean6SEM. A paired t test was used for
comparing data between two groups. For repeated-measurement
analysis, ANOVA was used, and the Student-Newman-Keuls test
was then performed. Data analyses were performed on absolute and
Selected Abbreviations and Acronyms
aCSF 5 artificial cerebrospinal fluid
AMPA 5 a-amino-3-hydroxy-5-methyl-4-isoxazolepropionate
CGRP 5 calcitonin gene–related peptide
H/I 5 hypoxia/ischemia
KATP 5 ATP-dependent potassium channels
KCa 5 calcium-dependent potassium channels
NMDA 5 N-methyl-D-aspartate
NO 5 nitric oxide
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percent change data. A P value ,.05 was regarded as statistically
significant.
Results
Before and after H/I, mean arterial blood pressures were
stable and within normal limits for piglets. For example, in
the NS1619 group, during baseline conditions arterial blood
pressures were 6464 mm Hg before H/I and 6362 mm Hg 1
hour after H/I. Arterial blood pressures were not affected by
the topical application of the drugs used in these experiments.
Arterial blood gases and pH were monitored regularly
during the experiments and were generally kept within the
physiological range. At baseline, pH was 7.4560, PCO2 was
3261 mm Hg, and PO2 was 10664 mm Hg (n532). After 8
minutes of hypoxia, pH was 7.4060, PCO2 was 3262 mm Hg,
and PO2 was 2761 mm Hg (n524). Arterial blood gases were
similar to baseline after recovery from H/I. Blood gases and
pH did not differ significantly among groups.
Application of NMDA before H/I caused a reproducible,
dose-dependent cerebral arteriolar dilation (Table, Fig 1).
After H/I, however, arteriolar responses to NMDA were
markedly reduced (Table, Fig 1). Subsequent administration
of sodium nitroprusside (1024 mol/L) caused consistent dila-
tion of the same vessels by 2562% compared with baseline.
Topical administration of the drugs 10 minutes before H/I
caused arteriolar dilation by 1564% for NS1619, 2667% for
aprikalim, 1564% for CGRP, and 2062% for papaverine.
Pretreatment with NS1619 (1025 mol/L) resulted in an
almost complete preservation of the arteriolar dilation to the
different concentrations of NMDA 1 hour after H/I (Table,
Fig 2), indicating no statistically significant difference be-
tween the preischemic and postischemic arteriolar responses.
Similarly, administration of aprikalim (1026 mol/L) preserved
the post-H/I vascular response to NMDA (Table). Percent
changes in vascular diameter to NMDA before and after H/I
were as follows: 662% versus 862% at 1025 mol/L, 2266%
versus 1563% at 531025 mol/L, and 4165% versus 3266%
at 1024 mol/L (n57, P..05). In contrast, piglets pretreated
with CGRP (1026 mol/L) showed a severe attenuation of the
vascular response to NMDA comparable to the group that did
not receive any pretreatment (Table). Vascular diameter
increased by 662% versus 060% at 1025 mol/L, 2265%
versus 261% at 531025 mol/L, and 2867% versus 261% at
1024 mol/L of NMDA. In addition, vascular responses to
NMDA were markedly attenuated after pretreatment with
papaverine (1025 mol/L). Arteriolar dilation before compared
with after H/I was 761% versus 361% at 1025 mol/L NMDA
and 3864% versus 1666% at 531025 mol/L NMDA (n55,
P,.05).
Administration of kainate (1024 mol/L) before H/I dilated
cerebral arterioles from a baseline of 10663 mm by 2764%.
One hour after H/I kainate induced a 2163% dilation from a
baseline of 11066 mm (P..05).
Arteriolar Dilation to NMDA Before and After H/I
NMDA Application Before H/I NMDA Application 1 h After H/I
Baseline 1025 mol/L 531025 mol/L 1024 mol/L Baseline 1025 mol/L 531025 mol/L 1024 mol/L
Group 1 (n57): none
Diameter 10162 10963 12366† 13465† 10464 10566 10966* 11166*
D Diameter 961 2264† 3364† 362 562* 762*
Group 2 (n56): NS1619
Diameter 10363 11263 12367† 13963† 10463 10963 12565† 13565†
D Diameter 961 2066† 3663† 662 2565† 3265†
Group 3 (n57): aprikalim
Diameter 10164 10765 12368† 14269† 10464 11366 12066† 13869†
D Diameter 662 2266† 4166† 962 1563† 3467†
Group 4 (n56): CGRP
Diameter 10464 11065 12767† 13368† 11267 11367 11468* 11869*
D Diameter 662 2365† 2967† 161 261* 361*
Values are mean6SEM, expressed in micrometers.
*Significantly different from respective preischemic value (P,.05).
†Significantly different from respective baseline.
Figure 1. Effects of H/I on cerebral arteriolar dilation to NMDA.
Cerebral arteriolar dilator responses to NMDA were significantly
decreased 1 hour after 10 minutes of hypoxia plus 10 minutes
of ischemia. Values are mean6SEM for 7 piglets. *Significantly
different from preischemic dilation (P,.05).
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Discussion
There are three major new findings from these experi-
ments: First, the vascular responsiveness of cerebral arte-
rioles to NMDA, which is attenuated after consecutive H/I,
was preserved by topical pretreatment with either NS1619
or aprikalim. Second, CGRP and papaverine did not
preserve the vascular response to NMDA, although they
caused dilation of the cerebral arterioles to an extent
similar to that of the potassium channel agonists before
H/I. Third, the kainate-induced arteriolar dilation was
largely preserved after H/I.
Cerebral arterioles do not possess NMDA receptors.17,18
Consequently, the NMDA-induced cerebral arteriolar dilation
can only take place through an indirect pathway involving
production, release, and action of NO. While the complete
sequence of mechanisms involved is currently unknown,
NMDA mainly causes cerebral arteriolar dilation through the
sequential production of neuronal NO and vascular smooth
muscle cGMP.1–5,19
In the present study the combined stress of H/I markedly
attenuated the response of cerebral arterioles to NMDA as
measured 1 hour after the insult. Previously, we have
shown that a period of 5 to 15 minutes of either ischemia,
asphyxia, or hypoxia is able to attenuate the NMDA-
induced arteriolar dilation.7,8,20 Administration of either
NS1619 or aprikalim, putatively selective agonists of KCa
channels13,21,22 and KATP channels,23–25 respectively, essen-
tially preserved the response of cerebral arterioles to
NMDA. The mechanism leading to this unprecedented
finding is as yet unclear. NS1619 and aprikalim can dilate
cerebral arterioles by the direct stimulation of potassium
channels on vascular smooth muscle cells.25–28 Therefore,
hypothetically, the preservation of the NMDA-induced
vascular response may take place as a consequence of
vasodilation before ischemia. This hypothesis, however, is
hard to reconcile with the observation that the similar
dilation of cerebral arterioles to CGRP and papaverine
before ischemia had little or no effect on the postischemic
vascular response to NMDA.
Several different subtypes of potassium channels (eg,
voltage-gated, ATP-dependent, calcium-dependent, inward
rectifier potassium channels) have been identified on
cells,14 and all subtypes are present on neurons.29 The
interaction of NS1619 and aprikalim with their respective
potassium channels on neurons therefore represents an
alternative mechanism through which their preservative
effect on the NMDA-mediated neuronal-vascular coupling
may have taken place. Although the gating mechanism and
conduction properties differ between subtypes, opening of
potassium channels generally leads to hyperpolarization of
excitable cells by increasing the efflux of potassium ions
from the relatively negatively charged intracellular com-
partment into the extracellular space. Current concepts of
H/I brain damage include the deleterious effects of exces-
sive secretion of neurotoxic excitatory neurotransmitters30
and the intracellular accumulation of calcium.31 Theoreti-
cally, potassium channel openers may counteract these
effects by hyperpolarizing presynaptic and postsynaptic
neurons.14,29 Potassium channel openers also may inhibit
the release of calcium from intracellular stores.14 This may
lead to decreased glutamate secretion, slowing of the
depolarization rate, diminished intracellular calcium accu-
mulation, lower energy consumption, and reduced produc-
tion of free oxygen radicals (Fig 3).
Experimental data supporting this attractive neuropro-
tective concept are sparse. Wind et al32 found protection of
cultured neurons against chemically induced hypoxia by
bimakalim, a KATP activator. Suzuki and coworkers33
showed that pretreatment with pinacidil, a partial KATP
agonist, shortened the recovery time of spinal reflexes
after spinal ischemia in cats. When glibenclamide, an
inhibitor of KATP, was coadministered, the protective effect
was absent. Similarly, in a study by Riepe et al,34 gliben-
clamide partly reversed increased hypoxic tolerance after
chemical inhibition of oxidative phosphorylation in hip-
pocampal slices. Zini et al15 reported that K1 channel
agonists blocked ischemia-induced glutamate release in rat
hippocampal slices. Using a rat model of global ischemia,
Heurteaux et al16 demonstrated that several KATP openers
administered intracerebroventricularly blocked the expres-
sion of immediate early genes in the hippocampus. The
same and a similar study by these authors16,35 also showed
a decrease in delayed neuronal death in hippocampal CA1
neurons. We are not aware of other studies examining the
Figure 2. Effects of NS1619 pretreatment on cerebral arteriolar
dilation to NMDA after H/I. Cerebral arteriolar responses to
NMDA were preserved 1 hour after 10 minutes of hypoxia plus
10 minutes of ischemia by NS1619 (1026 mol/L). Values are
mean6SEM for 6 piglets. n.s. indicates not significantly different
from preischemic dilation (P..05).
Figure 3. Potential mechanisms by which potassium channel
activators may protect the NMDA-induced cerebral arteriolar
dilation during and after H/I. Efflux of K1 through activated K1
channels leads to hyperpolarization of neurons. KATP/Ca indicates
ATP-dependent/calcium-dependent potassium channels; Cai11,
intracellular calcium concentration; and ROS, reactive oxygen
species.
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neuroprotective effect of KCa openers in cerebral hypoxia
and ischemia.
The methods in the present study do not allow us to
identify the precise molecular site at which NS1619 and
aprikalim preserved the NMDA-mediated neuronal-vascu-
lar coupling after H/I. We speculate that both types of
potassium channel openers preserved the NMDA-mediated
response by indirectly protecting the NMDA receptor
complex. Based on the results of previous work, we
suggested that the affected step in the NMDA-vasodilating
sequence may be the neuronal NMDA receptor rather than
NO synthesis or the action of subsequent metabolites.8,20
The present study partly supports this concept since the
arterioles, which did not respond to NMDA after H/I, still
dilated to sodium nitroprusside, an NO donor. Indeed, the
postischemic dilation to sodium nitroprusside (2562%)
was of an extent similar to that of previous preischemic
control measurements in the same experimental setup.
Moreover, the partially (approximately 80%) preserved
arteriolar response to kainate, which has been shown to be
mediated equally by NO and prostaglandins6 in this model,
suggests that neurons carrying glutamate receptors main-
tain some signaling mechanisms including stimulus-depen-
dent NO synthesis. However, we cannot rule out a com-
pensatory role of prostaglandins in kainate-induced
arteriolar dilation after H/I.
Holland et al36 demonstrated a neuroprotective effect of
intravenous CGRP in a rat model of focal ischemia. Since
CGRP does not easily cross the blood-brain barrier, the
authors speculated that the recorded increase in cerebral
blood flow may account for their findings. In contrast,
CGRP failed to preserve the NMDA-mediated neuronal-
vascular coupling in our experiments, although it dilated
cerebral arterioles before ischemia. CGRP exerts its vaso-
dilating effect largely through activation of KATP on smooth
muscle cells.37 In contrast to direct activators of potassium
channels (eg, aprikalim, NS1619), which are known to
hyperpolarize neurons, the effect of CGRP on neurons is
probably more complex and may depend on the neuronal
circuit involved. CGRP receptors have been shown to be
present in the porcine cortex,38 but we are not aware of any
study investigating the receptor density in certain cortical
layers or even colocalization with NMDA receptor–posi-
tive neurons. To our knowledge the relationship of CGRP
to neuronal potassium channels has never been studied.
From our experiments we can only conclude that CGRP
does not have a sufficient (if any) effect on neuronal K1
channels to preserve the NMDA-mediated vasodilating
sequence. The modest preservation of NMDA-induced
dilation by papaverine may be due to effects on neuronal
K1 channels or to other yet undisclosed neuroprotective
effects.
Even after the severe consecutive H/I stress, the vascular
responses to kainate were only attenuated by approxi-
mately 20%. This confirms the remarkable resistance of
the kainate-mediated neuronal-vascular sequence in gen-
eral and of the kainate receptor in particular, which we
reported recently.6 It also illustrates the selectivity of
damage caused by cerebral H/I affecting the response
linked to one glutamate receptor subtype while in part
sparing another.
We cautiously interpret our findings as indicative of a
neuroprotective effect of potassium channel agonists on
the postischemic function of neurons carrying the NMDA
receptor. The immediate implications of this specific
preservative effect for the overall protection of the brain
against ischemia are currently unknown. We suggest,
however, that the protective mechanisms of potassium
channel openers are unlikely to be confined to the NMDA
receptor but rather express their beneficial effect on
another, more general pathophysiological mechanism
in H/I.
The presented results may have clinical implications for
focal ischemic stroke or cerebral global ischemia after
heart arrest. Our experimental paradigm circumvents some
of the problems associated with the systemic administra-
tion of central nervous system drugs.39 In addition, postis-
chemic treatment may encounter altered receptor interfaces
favoring or disfavoring particular therapeutic strategies. In
the present study the drugs were applied before H/I when
receptors and signaling mechanisms were evidently intact.
Our recent work has shown that postischemic vasodilation
to KCa openers40 but not to KATP agonists is resistant to
ischemia.11 Although the vasodilation induced by potas-
sium channel openers is probably caused mainly by imme-
diate interaction with potassium channels on vascular
smooth muscle cells, the attenuated response to KATP
agonists may indicate the vulnerability and transient non-
responsiveness of the targeted receptor and pathway. If this
also involved neuronal KATP channels, they would become
a less attractive target for neuroprotection than KCa chan-
nels for treatment started in the early postischemic period.
In summary, our findings show that topical pretreatment
with the selective potassium channel openers NS1619 and
aprikalim preserves the NMDA-mediated neuronal-vascu-
lar coupling after H/I in newborn piglets. This finding
suggests considerable neuroprotective potential of these
agents.
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Editorial Comment
Acute episodes of cerebral ischemia followed by reperfu-
sion produce reactive hyperemia1 with subsequent reductions
in cerebral blood flow,2 disruption of the blood-brain barrier,3
damage to cerebrovascular endothelium,4 and impairment of
NO synthase– dependent reactivity of cerebral arteries.5
Mechanisms that contribute to impaired NO synthase–depen-
dent reactivity of cerebral arteries after cerebral ischemia are
unclear.
Recent evidence suggests that activators of K1 channels
may have potential therapeutic implications. It is possible that
K1 channel activators, by stimulating the efflux of potassium
ions from cellular compartments, may counteract ischemia-
induced depolarizations and thus protect the cerebral circu-
lation. Glutamate is an important neurotransmitter in the brain
and produces dilation of cerebral blood vessels, in part,
through activation of NMDA receptors and synthesis/release
of NO. Previous studies by this group6 and others7 have
shown that cerebral H/I impairs or abolishes dilation of
cerebral arterioles in response to NMDA. The purpose of the
present study was to determine whether treatment with K1
channel activators before cerebral H/I preserves NMDA-
induced arteriolar dilation.
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These investigators measured in vivo responses of piglet
cerebral arterioles to topical application of NMDA before and
after periods of cerebral H/I. The authors report impaired
responses of cerebral arterioles to NMDA after H/I. Pretreat-
ment with K1 channel activators (aprikalim and NS1619),
however, preserved arteriolar dilation to NMDA after cere-
bral H/I. Restoration in responses to NMDA after treatment
with K1 channel activators was specific since CGRP did not
alter responses to NMDA.
Thus, it appears that activation of K1 channels, presumably
on neurons, accounts for preservation in cerebrovascular
responses to NMDA after cerebral H/I. These findings sug-
gest a potentially important therapeutic role for activation of
K1 channels after cerebral ischemia.
William G. Mayhan, PhD, Guest Editor
Department of Physiology and Biophysics
University of Nebraska Medical Center
Omaha, Nebraska
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